Isaac R. Melamed
Elite in Primary Immunodeficiency (PID)

Dr. Isaac R. Melamed

Allergy and Immunology | Pediatrics
Veros Health
1551 Professional Lane, Suite 170, 
Longmont, CO 
Offers Telehealth

Elite in Primary Immunodeficiency (PID)
Veros Health
1551 Professional Lane, Suite 170, 
Longmont, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

With more than thirty-five years of experience working as a physician, Dr. Melamed is a respected leader in the fields of immunology and immune-related disease. He has spent over twenty-years researching immune-related disease, primary and secondary immune deficiency, and the link between the immune system and the central nervous system. Dr. Melamed's mission is to identify diseases early, to ensure his patient's optimal health.

Dr. Melamed is rated as an Elite provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Primary Immunodeficiency (PID), Common Variable Immune Deficiency, Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections, and Hereditary Angioedema.

His clinical research consists of co-authoring 37 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 22 articles and participated in 6 clinical trials in the study of Primary Immunodeficiency (PID).

Specialties
Allergy and Immunology
Pediatrics
Licenses
Allergy and Immunology in CO
Board Certifications
Allergy And Immunology
Languages Spoken
English
Gender
Male
Awards
Award of Clinical Immunology Society in 2002
Research Award of the American Academy of Allergy and Immunology in 1993
isdale Award for Excellence in Research in 1990

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

Veros Health
1551 Professional Lane, Suite 170, Longmont, CO 80501
Other Locations
Veros Health
6801 South Yosemite Street, Centennial, CO 80112
Veros Health
3240 East 104th Avenue, Thornton, CO 80233

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


17 Clinical Trials

A Phase 1a/1b Study of OPT101 in Healthy Volunteers
A Phase 1a/1b Study of OPT101 in Healthy Volunteers
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double Blind, Placebo Controlled, Cross-Over, Proof-of-Concept Study to Evaluate the Benefit of RUCONEST (C1 Esterase Inhibitor [Recombinant]) in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection
A Randomized, Double Blind, Placebo Controlled, Cross-Over, Proof-of-Concept Study to Evaluate the Benefit of RUCONEST (C1 Esterase Inhibitor [Recombinant]) in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Drug
Study Drug: Ruconest
Study Phase: Phase 2
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 1 Open-label, Multi-centre, Single-arm Trial to Evaluate the Safety and Pharmacokinetics (Including MUsT) of Twice Daily Topical Application of Delgocitinib Cream for 8 Weeks in Adults, Adolescents, and Children With Moderate to Severe Atopic Dermatitis
A Phase 1 Open-label, Multi-centre, Single-arm Trial to Evaluate the Safety and Pharmacokinetics (Including MUsT) of Twice Daily Topical Application of Delgocitinib Cream for 8 Weeks in Adults, Adolescents, and Children With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2025
Intervention Type: Drug
Study Drug: Delgocitinib Cream
Study Phase: Phase 1
An Open-Label Extension Study of CM-AT for the Treatment of Children With Autism With All Levels of Fecal Chymotrypsin
An Open-Label Extension Study of CM-AT for the Treatment of Children With Autism With All Levels of Fecal Chymotrypsin
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drug: CM-AT Enzyme
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2025
Intervention Type: Drug
Study Drug: Rilzabrutinib
Study Phase: Phase 3
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
Expanded Access Program: Lanadelumab for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Patients 2 to <12 Years of Age and Lanadelumab for the Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Expanded Access Program: Lanadelumab for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Patients 2 to <12 Years of Age and Lanadelumab for the Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: No_longer_available
Publish Date: July 24, 2023
Intervention Type: Drug
A Double Blind, Randomized, Placebo-Controlled Study of CM-AT for the Treatment of Autism in Children With All Levels of Fecal Chymotrypsin (FCT)
A Double Blind, Randomized, Placebo-Controlled Study of CM-AT for the Treatment of Autism in Children With All Levels of Fecal Chymotrypsin (FCT)
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological
Study Drugs: HYQVIA, Intravenous Immunoglobulin G
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects 2 to <12 Years of Age
SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects 2 to <12 Years of Age
Enrollment Status: Completed
Publish Date: May 26, 2022
Intervention Type: Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and PK of ProMetic BioTherapeutics IGIV (Human) 10% in Adults and Children With Primary Immunodeficiency Diseases
A Phase 3, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and PK of ProMetic BioTherapeutics IGIV (Human) 10% in Adults and Children With Primary Immunodeficiency Diseases
Enrollment Status: Completed
Publish Date: November 05, 2021
Intervention Type: Biological
Study Phase: Phase 3
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
Enrollment Status: Completed
Publish Date: August 24, 2021
Intervention Type: Biological
Study Phase: Phase 3
A Single-site, Open-Label, Pilot Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions
A Single-site, Open-Label, Pilot Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Biological
Study Phase: Phase 4
A Multi-site, Open-Label, Pilot Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
A Multi-site, Open-Label, Pilot Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
Enrollment Status: Unknown
Publish Date: November 19, 2019
Intervention Type: Biological
Study Drug: Immunoglobulin
Study Phase: Phase 4
Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Enrollment Status: Completed
Publish Date: August 07, 2019
View 16 Less Clinical Trials

37 Total Publications

Long-term Safety and Effectiveness of Sebetralstat: Interim Analysis of KONFIDENT-S Open-label Extension.
Long-term Safety and Effectiveness of Sebetralstat: Interim Analysis of KONFIDENT-S Open-label Extension.
Journal: The journal of allergy and clinical immunology. In practice
Published: May 16, 2025
View All 37 Publications
Similar Doctors
Advanced in Primary Immunodeficiency (PID)
Dr. Karen M. Andrews
Allergy and Immunology
Advanced in Primary Immunodeficiency (PID)
Dr. Karen M. Andrews
Allergy and Immunology

Boulder Medical Center, PC

2750 Broadway St, 
Boulder, CO 
 (36.5 miles away)
303-440-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Karen Andrews is an Allergy and Immunologist in Boulder, Colorado. Dr. Andrews is rated as an Advanced provider by MediFind in the treatment of Primary Immunodeficiency (PID). Her top areas of expertise are Primary Immunodeficiency (PID), Sinusitis, Allergic Rhinitis, and Grass Allergy. Dr. Andrews is currently accepting new patients.

Edan Sarid
Advanced in Primary Immunodeficiency (PID)
Dr. Edan Sarid
Allergy and Immunology | Pediatrics
Advanced in Primary Immunodeficiency (PID)
Dr. Edan Sarid
Allergy and Immunology | Pediatrics

Veros Health

1551 Professional Lane, Suite 170, 
Longmont, CO 
 (39.4 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Sarid is a dedicated board-certified physician specializing in the practice of adult and pediatric allergy, asthma and immunology. His particular interest is in managing complex immunologic and allergic diseases through the identification and modification of defects in the immune system that cause inflammation. Dr. Sarid began his career in New York as a pediatric hospitalist and urgent care physician and then pursued his life-long interest in allergy, asthma and immunology by completing a subspecialty fellowship at the State University of New York Downstate Medical Center in Brooklyn. There he completed multiple research projects on the long term effects of chronic treatments in immune diseases.After moving to Colorado and joining IMMUNOe Health Centers, Dr. Sarid is utilizing his background in pediatrics and global medicine to provide devoted and passionate care for his patients and for cutting-edge clinical research. Outside of medicine, Dr. Sarid finds leisure in composing and performing his music on the piano as well as discovering Colorado’s beautiful outdoors with his family. Dr. Sarid is rated as an Advanced provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Common Variable Immune Deficiency, Primary Immunodeficiency (PID), Hereditary Angioedema, and Hyperphenylalaninemia Due to Dehydratase Deficiency.

Advanced in Primary Immunodeficiency (PID)
Dr. Kevin P. O'brien
Allergy and Immunology
Advanced in Primary Immunodeficiency (PID)
Dr. Kevin P. O'brien
Allergy and Immunology
3260 E 104th Ave, 
Thornton, CO 
 (20.4 miles away)
720-929-8300
Languages Spoken:
English
See accepted insurances

Kevin O'brien is an Allergy and Immunologist in Thornton, Colorado. Dr. O'brien is rated as an Advanced provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Common Variable Immune Deficiency, Primary Immunodeficiency (PID), Complement Component 2 Deficiency, and Hyperphenylalaninemia Due to Dehydratase Deficiency.

VIEW MORE PRIMARY IMMUNODEFICIENCY (PID) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Melamed's expertise for a condition
ConditionClose
  • Elite
  • Primary Immunodeficiency (PID)
    Dr. Melamed is
    Elite
    . Learn about Primary Immunodeficiency (PID).
    See more Primary Immunodeficiency (PID) experts
  • Distinguished
  • Common Variable Immune Deficiency
    Dr. Melamed is
    Distinguished
    . Learn about Common Variable Immune Deficiency.
    See more Common Variable Immune Deficiency experts
  • Hereditary Angioedema
    Dr. Melamed is
    Distinguished
    . Learn about Hereditary Angioedema.
    See more Hereditary Angioedema experts
  • Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections
    Dr. Melamed is
    Distinguished
    . Learn about Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections.
    See more Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections experts
  • X-Linked Agammaglobulinemia
    Dr. Melamed is
    Distinguished
    . Learn about X-Linked Agammaglobulinemia.
    See more X-Linked Agammaglobulinemia experts
  • Advanced
  • Angioedema
    Dr. Melamed is
    Advanced
    . Learn about Angioedema.
    See more Angioedema experts
  • Asthma
    Dr. Melamed is
    Advanced
    . Learn about Asthma.
    See more Asthma experts
  • Complement Component 2 Deficiency
    Dr. Melamed is
    Advanced
    . Learn about Complement Component 2 Deficiency.
    See more Complement Component 2 Deficiency experts
  • Hives
    Dr. Melamed is
    Advanced
    . Learn about Hives.
    See more Hives experts
  • Hyperphenylalaninemia Due to Dehydratase Deficiency
    Dr. Melamed is
    Advanced
    . Learn about Hyperphenylalaninemia Due to Dehydratase Deficiency.
    See more Hyperphenylalaninemia Due to Dehydratase Deficiency experts
  • Experienced
  • Allergic Rhinitis
    Dr. Melamed is
    Experienced
    . Learn about Allergic Rhinitis.
    See more Allergic Rhinitis experts
  • Alpha-1 Antitrypsin Deficiency (AATD)
    Dr. Melamed is
    Experienced
    . Learn about Alpha-1 Antitrypsin Deficiency (AATD).
    See more Alpha-1 Antitrypsin Deficiency (AATD) experts
  • Autism Spectrum Disorder
    Dr. Melamed is
    Experienced
    . Learn about Autism Spectrum Disorder.
    See more Autism Spectrum Disorder experts
  • Chronic Cough
    Dr. Melamed is
    Experienced
    . Learn about Chronic Cough.
    See more Chronic Cough experts
  • Grass Allergy
    Dr. Melamed is
    Experienced
    . Learn about Grass Allergy.
    See more Grass Allergy experts
  • IgG4-Related Disease
    Dr. Melamed is
    Experienced
    . Learn about IgG4-Related Disease.
    See more IgG4-Related Disease experts
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved

    Request a Doctor Appointment

    Please fill out the details in the form below to allow MediFind to submit an appointment request to Dr. Isaac R. Melamed's office on your behalf. Your provider may contact you directly to complete scheduling. If you are experiencing a medical emergency, please call 9-1-1. This form is for appointment requests only. Currently, we are not accepting appointments from users outside of the US.

        Close
        0 / 1000

        Please provide us with the below insurance information:

        By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.